S'abonner

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial - 06/08/11

Doi : 10.1016/S1470-2045(10)70290-4 
Christopher M Nutting, DrFRCR a, b, , James P Morden, MSc b, Kevin J Harrington, FRCR a, b, Teresa Guerrero Urbano, PhD c, Shreerang A Bhide, FRCR a, Catharine Clark, PhD d, Elizabeth A Miles, MPhil e, Aisha B Miah, FRCR a, Kate Newbold, FRCR a, MaryAnne Tanay, MSc a, Fawzi Adab, FRCR f, Sarah J Jefferies, FRCR g, Christopher Scrase, FRCR h, Beng K Yap, FRCR i, Roger P A’Hern, MSc b, Mark A Sydenham, BSc b, Marie Emson, BSc b, Emma Hall, PhD b

on behalf of the PARSPORT trial management group

  Details given in the Web Extra Material

a Head and Neck Unit, Royal Marsden Hospitals NHS Foundation Trust, London, UK 
b Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, Surrey, UK 
c Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK 
d Department of Medical Physics, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK 
e National Radiotherapy Trials QA Group, Mount Vernon Hospital, Northwood, UK 
f Cancer Centre, University Hospital of North Staffordshire NHS Trust, Stoke on Trent, UK 
g Oncology Centre, Addenbrooke’s Hospital NHS Foundation Trust, Cambridge, UK 
h Department of Clinical Oncology, The Ipswich Hospital NHS Trust, Ipswich, UK 
i Department of Radiotherapy, The Christie NHS Foundation Trust, Manchester, UK 

* Correspondence to: Dr Christopher M Nutting, ICR-CTSU, Section of Clinical Trials, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK

Summary

Background

Xerostomia is the most common late side-effect of radiotherapy to the head and neck. Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia.

Methods

We undertook a randomised controlled trial between Jan 21, 2003, and Dec 7, 2007, that compared conventional radiotherapy (control) with parotid-sparing IMRT. We randomly assigned patients with histologically confirmed pharyngeal squamous-cell carcinoma (T1–4, N0–3, M0) at six UK radiotherapy centres between the two radiotherapy techniques (1:1 ratio). A dose of 60 or 65 Gy was prescribed in 30 daily fractions given Monday to Friday. Treatment was not masked. Randomisation was by computer-generated permuted blocks and was stratified by centre and tumour site. Our primary endpoint was the proportion of patients with grade 2 or worse xerostomia at 12 months, as assessed by the Late Effects of Normal Tissue (LENT SOMA) scale. Analyses were done on an intention-to-treat basis, with all patients who had assessments included. Long-term follow-up of patients is ongoing. This study is registered with the International Standard Randomised Controlled Trial register, number ISRCTN48243537.

Findings

47 patients were assigned to each treatment arm. Median follow-up was 44·0 months (IQR 30·0–59·7). Six patients from each group died before 12 months and seven patients from the conventional radiotherapy and two from the IMRT group were not assessed at 12 months. At 12 months xerostomia side-effects were reported in 73 of 82 alive patients; grade 2 or worse xerostomia at 12 months was significantly lower in the IMRT group than in the conventional radiotherapy group (25 [74%; 95% CI 56–87] of 34 patients given conventional radiotherapy vs 15 [38%; 23–55] of 39 given IMRT, p=0·0027). The only recorded acute adverse event of grade 2 or worse that differed significantly between the treatment groups was fatigue, which was more prevalent in the IMRT group (18 [41%; 99% CI 23–61] of 44 patients given conventional radiotherapy vs 35 [74%; 55–89] of 47 given IMRT, p=0·0015). At 24 months, grade 2 or worse xerostomia was significantly less common with IMRT than with conventional radiotherapy (20 [83%; 95% CI 63–95] of 24 patients given conventional radiotherapy vs nine [29%; 14–48] of 31 given IMRT; p<0·0001). At 12 and 24 months, significant benefits were seen in recovery of saliva secretion with IMRT compared with conventional radiotherapy, as were clinically significant improvements in dry-mouth-specific and global quality of life scores. At 24 months, no significant differences were seen between randomised groups in non-xerostomia late toxicities, locoregional control, or overall survival.

Interpretation

Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck.

Funding

Cancer Research UK (CRUK/03/005).

Le texte complet de cet article est disponible en PDF.

Plan


© 2011  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 12 - N° 2

P. 127-136 - février 2011 Retour au numéro
Article précédent Article précédent
  • Critical care: a nurse faces death, life, and everything in between
  • Sian Maslin-Prothero
| Article suivant Article suivant
  • A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment
  • Steven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, Yuanbin Ru, Kuan-Fu Ding, Christopher A Moskaluk, Yves Fradet, Jan Lehmann, Michael Stöckle, Arndt Hartmann, Jae K Lee, Dan Theodorescu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.